ClinicalTrials.gg
CompletedNCT05681182CAMP POAFUpdated Nov 5, 2026Results posted

Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone

A Phase 4 interventional study of CardiaMend with the Addition of Amiodarone in Post Operative Atrial Fibrillation, sponsored by WakeMed Health and Hospitals. Completed at 1 site in United States. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by WakeMed Health and Hospitals · Phase 4, Interventional, and Prevention

How we know

Updated Nov 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
532nd of 679
30 · median 127
Started
2023
with 54 others
Phase 4
87 of 993
10 open now
Registered
809th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 532nd largest by enrollment of the 679 interventional ones that give a count, is one of 55 that started in 2023, is one of 87 in phase 4, and was the 809th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing isolated cardiac arterial bypass grafting (CABG) or valve surgery.

Read the detailed description

This study will investigate CardiaMend, an FDA cleared (K210331) pericardial reconstruction matrix used in combination with amiodarone, an FDA approved antiarrhythmic drug, as a prevention of POAF.

This is a single-center, prospective, pilot study, enrolling adult subjects undergoing isolated cardiac arterial bypass surgery or isolated valve surgery, via complete median sternotomy.

CardiaMend should be used according to the Instructions for Use with the exception that device hydration is performed with 3 ampules of amiodarone (150mg/3ml) instead of room temperature saline. For best results, the device should be fixed in place using a continuous or interrupted stitch (approximately 1 stitch per cm) to approximate the edge of the pericardial defect. The closed defect should not put pressure on the underlying structures. A non-absorbable monofilament suture is preferred such as 5-0 or 4-0 prolene. A small edge may be left open for drain placement and a small slit for LIMA in case of CABG.

Patients will have continuous EKG until discharge. If clinically indicated, patients will receive a monitor for home monitoring per standard of care.

03

Conditions studied

  • Post Operative Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject aged 20-85 years old.
  • Patients able to provide written , understand, and be willing to comply with study-related procedures.
  • Participants who are scheduled to undergo open-chest cardiac surgery via complete median sternotomy. Includes:

    • Coronary artery bypass graft (CABG) or valve repair/replacement, or
    • Inclusionary valve repair/replacement procedures for the primary reason for surgery include: aortic valve repair/replacement, mitral valve repair/replacement.
    • Note: Left atrial appendage (LAA) procedures are allowed if CABG and/or valve repair or replacement is the qualifying surgical procedure, but is not a qualifying surgical procedure on its own.
  • In sinus rhythm at the time of office visit and prior (note: continuous EKG monitoring for 48 hours is not required).

Exclusion criteria

Exclusion Criteria:

  • Subject unable to give voluntary written , is unlikely to cooperate or is legally incompetent, including subjects who are institutionalized by court or official order, or in a dependency relationship with, testing center or investigator.
  • Any condition which could interfere with the subject's ability to comply with the study.
  • Ongoing participation in an interventional clinical study or during the preceding 30 days.
  • Female subjects who are pregnant, breastfeeding, were pregnant within the last three months, or are planning to become pregnant during the course of the study.
  • Active skin or deep infection at the site of implantation.
  • History of chronic wounds or wound-healing disorders.
  • Known connective tissue diseases (e.g. Ehlers-Danlos syndrome, Epidermolysis bullosa, Marfan syndrome, Osteogenesis imperfecta).
  • Immune-suppressed subjects, immune-deficiency subjects (properly managed diabetes mellitus is not an exclusion criterion).
  • Concomitant oral or IV systemic therapy and/or other constant anti-inflammatory therapies.
  • The subject has an implantable cardiac device (i.e., cardiac resynchronization therapy devices with and without defibrillator capabilities (CRTs and CRT-Ds), implantable cardioverter-defibrillators (ICD) and pacemakers).
  • Known history of atrial fibrillation or paroxysmal atrial fibrillation.
  • History of ablation for atrial fibrillation.
  • Patients already receiving amiodarone as a treatment for atrial fibrillation or ventricular arrhythmias.
  • Disease of the left pleura, previous intervention in the left pleural space, or chest deformity.
  • Subjects with end-stage chronic-renal disease / dialysis.
  • Subjects with heart failure (BNP>1000), low (\<35%), end stage renal disease (on dialysis or creatinine >1.8).
  • STS risk >5.5% for 30 day mortality.
  • Patients electing to receive an ablative procedure for atrial fibrillation during the index operation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Single Arm

    All patients who are enrolled into the study will receive the treatment. This includes the CardiaMend which should be used according to the Instructions for Use with the exception that device hydration is performed with 3 ampules of amiodarone (150mg/3ml) instead of room temperature saline. For best results, the device should be fixed in place using a continuous or interrupted stitch (approximately 1 stitch per cm) to approximate the edge of the pericardial defect. The closed defect should not put pressure on the underlying structures. A non-absorbable monofilament suture is preferred such as 5-0 or 4-0 prolene. A small edge may be left open for drain placement and a small slit for LIMA in case of CABG

    Combination Product: CardiaMend with the Addition of Amiodarone

Interventions

  • Combination productCardiaMend with the Addition of Amiodarone

    The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.

06

What researchers measure

Primary outcomes

  1. Post Operative Atrial Fibrillation

    The patient will have continuous ECG monitoring until discharge to evaluate for any evidence of atrial fibrillation or atrial flutter which lasts longer than one hour or if less than one hour, requires medical or procedural intervention

    Time frame: On Average of one Week

07

Results

Posted Nov 5, 2026
Limitations and caveats
30 patient pilot study

Participant flow

Participant flow — Overall Study
MilestoneSingle Arm
Started30
Completed29
Not completed1
Withdrew: Developed atrial fibrillation prior to surgery; no longer met eligibility1

Outcome measures

PrimaryPost Operative Atrial Fibrillation

The patient will have continuous ECG monitoring until discharge to evaluate for any evidence of atrial fibrillation or atrial flutter which lasts longer than one hour or if less than one hour, requires medical or procedural intervention

Time frame:
On Average of one Week
Reported as:
Number · percentage of patients with AFib
Post Operative Atrial Fibrillation
percentage of patients with AFibSingle Arm
Post Operative Atrial Fibrillation30 (0 to 100)

Adverse events

Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm0/30 (0%)0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single Arm
<=18 years0
Between 18 and 65 years10
>=65 years20
Age, Continuous
Age, Continuous(years)Single Arm
Median69 (45 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female4
Male26
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm
American Indian or Alaska Native1
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White25
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Single Arm
United States30
08

Study locations

1 site
  • WakeMed Health and Hospitals
    Raleigh, North Carolina 27610, United States
09

References and documents

Publications

  • Rego A, Cheung PC, Harris WJ, Brady KM, Newman J, Still R. Pericardial closure with extracellular matrix scaffold following cardiac surgery associated with a reduction of postoperative complications and 30-day hospital readmissions. J Cardiothorac Surg. 2019 Mar 15;14(1):61. doi: 10.1186/s13019-019-0871-5. PubMed 30876459 ↗
  • Echahidi N, Pibarot P, O'Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008 Feb 26;51(8):793-801. doi: 10.1016/j.jacc.2007.10.043. PubMed 18294562 ↗
  • Lowres N, Mulcahy G, Jin K, Gallagher R, Neubeck L, Freedman B. Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2018 Mar 1;26(3):504-511. doi: 10.1093/icvts/ivx348. PubMed 29161419 ↗
  • Habbab LM, Chu FV. Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation. J Card Surg. 2016 Apr;31(4):253-8. doi: 10.1111/jocs.12700. Epub 2016 Feb 2. PubMed 26833498 ↗
  • Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008 Jul 21;127(3):299-306. doi: 10.1016/j.ijcard.2007.11.006. Epub 2008 Jan 8. PubMed 18191470 ↗
  • Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D; American Association for Thoracic Surgery. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg. 2014 Sep;148(3):e153-93. doi: 10.1016/j.jtcvs.2014.06.036. Epub 2014 Jun 30. No abstract available. PubMed 25129609 ↗
  • Beau J, Kulik A. Topical amiodarone to prevent postoperative atrial fibrillation: Need for further study. J Thorac Cardiovasc Surg. 2016 Feb;151(2):600. doi: 10.1016/j.jtcvs.2015.10.007. No abstract available. PubMed 26806512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Feb 2024, 12 months.

Results were first posted in Nov 2026, 2 years 8 months after primary completion.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 12 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2022
First posted
Jan 12, 2023
StartActual
Jan 20, 2023
Primary completionActual
Feb 6, 2024
CompletionActual
Feb 6, 2024
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time framePost Operative Atrial FibrillationThrough discharge, an average of 2 weeks → On Average of one Week
  • DescriptionPost Operative Atrial Fibrillation: how it is measured was reworded
Nov 5, 2026
Documents
Nov 5, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedAdditional Hospital Time Required Due to Atrial Fibrillation/FlutterTime frame: Through discharge, an average of 2 weeks
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time framePost Operative Atrial FibrillationThrough discharge, an average of 2 weeks → On Average of one Week
    • DescriptionPost Operative Atrial Fibrillation: how it is measured was reworded
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedAdditional Hospital Time Required Due to Atrial Fibrillation/FlutterTime frame: Through discharge, an average of 2 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05681182
Lead sponsor
WakeMed Health and Hospitals
Collaborators
Helios Cardio Inc.
Responsible party
Judson Williams (Principal Investigator, WakeMed Health and Hospitals) — Principal investigator
First posted
Jan 12, 2023
Start date
Jan 20, 2023
Primary completion
Feb 6, 2024
Completion
Feb 6, 2024
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Judson B Williams, MD
principal investigator · WakeMed Health and Hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion